Our scientists recognize that no two cancers--and no two cancer patients--are the same. We focus on finding the weaknesses in an individual’s cancer and the PARIS® Test identifies personalized treatment options for each patient’s unique tumor.

To learn more or to have your doctor schedule your test, visit our how to order page or direct questions to care@senginemedicine.com

Why consider the PARIS® Test?

Every patient's cancer is different and deserves personalized treatment. The PARIS® Test serves as a complementary tool to next-generation sequencing (NGS) testing, offering additional insights into actionable treatments.

The PARIS® Test is a drug sensitivity assay that starts with a tumor sample that is shipped to our laboratory.
The results are used to generate a CLIA-certified report that ranks the sample's drug response, providing information to the patient's oncologist about potential treatment options. The results assist an oncologist in selecting drugs that may be effective for an individual patient's cancer, but do not guarantee a definitive treatment outcome or response.
Results are typically available in approximately 4 to 6 weeks from tumor resection/biopsy.

Personalized medicine starts with the understanding that no two cancers are the same. Your tumor is unique and must be treated as such. Just as Paris slayed the invulnerable Achilles, SEngine developed the PARIS® Test to find the hidden vulnerabilities of your cancer. SEngine employs high-throughput screening to test selected drugs and drug combinations on cancer cells extracted from your tumor. We combine the results with advanced bioinformatics to prioritize drugs that match your unique tumor profile.

Personalized: We are testing the drugs on your very own cancer cells.

Aimed: We find the Achilles’ heel specific for your cancer.

Robotic testing allows us to rapidly test hundreds of drugs.

Informatics: The large amount of data derived from your tumor is analyzed and carefully prepared for your oncologist.

Sequencing: Deep DNA sequencing helps determine which mutations are driving a patient’s cancer and should be targeted.

Order Now

"SEngine Precision Medicine is on a truly innovative path. They are doing personalized medicine that will really make a difference for patients."

--Dr. Barbara Goff, UW Professor and Division Director, Gynecology Oncology

"Cancer is unique to everyone. As a person with Stage 4 Ovarian cancer and limited treatment options, The Paris Test provided me personalized options for cancer treatments that were specific to my cancer. It's time we moved past the standard of care. The Paris Test is the Precision Medicine we have been waiting for."

- Ingrid K., Oncology Patient